Organisation paid for research Program year 2025 Source: CMS Open Payments

Holston Medical Group PC

Neither a doctor nor a teaching hospital

Research payments

$2,050,969

544 payments

Through program year 2025, Holston Medical Group PC is reported as receiving $2,050,969 in research payments, across 544 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $33,061 14
2024 Research $69,419 21
2023 Research $80,853 34
2022 Research $213,421 56
2021 Research $410,790 71
2020 Research $342,364 136
2019 Research $901,061 212

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $696,057 41 payments
  2. Novo Nordisk AS $643,339 112 payments
  3. Pfizer Inc. $354,022 170 payments
  4. Allergan Inc. $86,897 28 payments
  5. GlaxoSmithKline, LLC. $76,970 45 payments
  6. AbbVie, Inc. $61,783 72 payments
  7. Kowa Research Institute, Inc. $50,158 29 payments
  8. Novavax Inc $22,066 20 payments
  9. Merck Sharp & Dohme Corporation $20,035 5 payments
  10. Boston Scientific Corporation $14,376 13 payments
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After An Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (Surmount-3) $295,842 4 payments
  2. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $180,512 9 payments
  3. Ex9536-4388 $119,579 25 payments
  4. Nn1250-4252 $107,713 8 payments
  5. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $98,399 54 payments
  6. Nn9536-4376 $89,199 12 payments
  7. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $85,582 34 payments
  8. Nn9536-4378 $66,110 12 payments
  9. Nn9838-4433 $65,209 14 payments
  10. Nn2211-4232 $61,953 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record